Multiple myeloma (MM) is a B-cell malignancy that remains incurable in most patients. After treatment with high-dose chemotherapy and autologous stem-cell support, complete remission rates of 50% are achieved. However, relapses are inevitable in most patients. Additional measures are needed after transplantation to eliminate minimal residual disease, and immunotherapy is an appealing option for this purpose. We hypothesize that optimized dendritic cell (DC)-based immunotherapies are able to elicit a strong myeloma-specific cytotoxic immune response in immunocompetent patients that may effectively control or even eradicate residual tumor cells. Compared to idiotype protein (Id), myeloma cells contain a multitude of tumor antigens that can stimulate an increased repertoire of anti-tumor T cells. Indeed, our preliminary results demonstrate that myeloma lysate-specific T cells are promising effector cells for immunotherapy. In this project, we propose to examine the efficacy of intranodal vaccination of myeloma patients with tumor antigen-pulsed, CD40L-conditioned mature DCs. Newly diagnosed, untreated patients (most of who have nearly intact immune systems) will be targeted, and DC vaccines will be given to the patients prior to and after high-dose therapy in order to achieve a maximal tumor reduction without compromising the effects of immunotherapy. Thus, aim 1 of this project is to evaluate anti-tumor immune and clinical responses in patients receiving Id versus tumor lysate-pulsed DCs, to determine whether tumor lysate-pulsed DCs induce stronger responses. Antigens and keyhole limpet hemocyanin (KLH)-pulsed, CD40L-matured DCs will be used as the vaccine. CD40L-conditioned/matured DCs can activate CD8+ T cells directly and break T-cell tolerance.
In Aim 2, we will evaluate whether re-infusion of blood T cells collected after initial DC vaccination helps to further expand specific T cells in vivo.
Aim 3 is to evaluate whether long-term booster immunization could further augment anti-tumor immune and clinical responses in patients, and aim 4 to elucidate the biological mechanisms of the immunotherapy strategies by examining the induction, number and function of myeloma-specific T cells and subsets in blood and bone marrow of patients and whether immunotherapy may induce epitope spreading and loss of tumor antigens by myeloma cells. Anti-myeloma immunological and clinical responses are the primary and secondary end points of the studies. These innovative approaches will substantially contribute to the ability of immunotherapy to induce or improve long-term survival in patients with MM.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA103978-05
Application #
7255724
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Merritt, William D
Project Start
2004-07-01
Project End
2009-05-31
Budget Start
2007-08-24
Budget End
2008-05-31
Support Year
5
Fiscal Year
2007
Total Cost
$277,385
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Haiyan; Lu, Yong; Qian, Jianfei et al. (2014) Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-? and CD40 ligand in vitro. J Bone Miner Res 29:2666-75
Park, Jungsun; Li, Haiyan; Zhang, Mingjun et al. (2014) Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother 63:835-45
Hong, S; Li, H; Qian, J et al. (2012) Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol 170:167-77
Hong, Sungyoul; Qian, Jianfei; Li, Haiyan et al. (2012) CpG or IFN-? are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61:561-71
Zheng, Yuhuan; Yang, Jing; Qian, Jianfei et al. (2012) Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90:695-706
Yang, Jing; Yi, Qing (2011) Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res 1:22-33
Yang, Jing; Yi, Qing (2010) Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116:1638-45
Yi, Qing; Szmania, Susann; Freeman, John et al. (2010) Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol 150:554-64
Li, Haiyan; Hong, Sungyoul; Qian, Jianfei et al. (2010) Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116:210-7
Yang, Jing; Cao, Yabing; Hong, Sungyongl et al. (2009) Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15:951-9

Showing the most recent 10 out of 24 publications